Chitosan-based mucoadhesive gel for oral mucosal toluidine blue O delivery: The influence of a non-ionic surfactant

Photodynamic therapy (PDT) has been successfully employed in the treatment of oral cancer. Toluidine blue O (TBO) is a photosensitizer (PS) that has exhibited remarkable photocytotoxicity in a variety of tumour cells; however, its physicochemical properties, as well as the physicochemical properties of oral mucosa, prevent the drug from reaching the target site at a therapeutic concentration.The aim of this study was to evaluate the influence of Tween 80^® (TW), which has shown potential as a penetration enhancer, on the mucosal retention of TBO for the PDT of oral cancer. 4% Chitosan-based mucoadhesive gels (CH gels) containing or not 5%TW were prepared (both containing 1%TBO), and their physicochemical properties (pH, rheology and mucoadhesion), TBO in vitro release profiles and TBO in vitro mucosal retention were evaluated. In vivo mucosal penetration studies of TBO followed by laser exposition were also carried out.The results showed that 4%CH gels containing 5%TW and 1%TBO have adequate mucoadhesive and rheological properties for oral mucosa use, although they present a slightly acid pH. TBO release studies showed that TW reduces TBO release, but it prolongs TBO release and increases TBO retention in the mucosa. In vivo studies showed that 4%CH gels containing 5%TW and 1%TBO cause an increase in the number of apoptotic cell, after laser exposition.In summary, 4%CH gels containing 5%TW may be a promising vehicle to optimize the penetration of TBO in oral mucosa and to improve the PDT response for the treatment of oral cancer.     

生物黏附性三七总皂苷-白及多糖-海藻酸钠复合微球的制备及表征

目的利用白及多糖(BSP)的生物黏附性,与海藻酸钠(SA)混合作为复合载体,以具有缓释特性的三七总皂苷(PNS)分散体作为包封药物,制备具有生物黏附性的PNS-BSP-SA复合微球。方法采用离子交联法制备微球,通过单因素试验和正交设计考察并优化处方工艺。通过扫描电镜(SEM)、粒径分布、差示扫描量热法(DSC)分析、溶胀性能测定、体外黏附性能评价、体外释放研究对微球进行表征。结果 PNS-BSP-SA复合微球圆整度较好,表面粗糙不平有褶皱,粒径分布较窄,PNS原料药以无定形状态均匀分散于微球中。最佳处方工艺制备的微球工艺稳定,重现性较好,与直接加入PNS原料药制备的微球相比,PNS分散体微球的载药量、包封率和得率均明显增加,分别为10.34%、51.25%、82.21%,而PNS原料药微球的载药量、包封率、得率分别为4.04%、12.16%、61.35%。BSP的加入增加了SA微球的溶胀性能,明显增加了其在大鼠胃部的滞留率。PNS-BSP-SA复合微球中人参皂苷Rg1的释放较PNS原料药缓慢。结论 BSP增加了微球的生物黏附性,将PNS制备为分散体,提高了微球的载药量、包封率和得率,并使微球具有一定的缓释性能。     

Buccal Transmucosal Delivery of Calcitonin in Rabbits Using Thin-Film Composites

Purpose. Salmon Calcitonin (sCT) is used to treat hypercalcemia resulting from Paget's disease and osteoporosis. sCT is available either in a sterile injectable form or nasal spray. Alternative and more cost-effective dosage forms for the delivery of calcitonin are needed. We sought to deliver sCT transmucosally using a previously reported mucoadhesive bilayer thin-film composite (TFC) via the buccal route. Methods. Forty micrograms of salmon calcitonin (200-IU) was loaded on preformed TFCs. In vitro release of sCT from TFCs was monitored in phosphate-buffered saline (10 mM, pH 7.4) at 37°C. Female New Zealand White rabbits (n = 6) were dosed with 40 g of sCT either by injection via the ear vein or by applying sCT-loaded TFCs directly on the buccal pouch. Blood was collected at various times, and the plasma sCT and calcium concentrations were quantified. WinNonlin® was used to determine the relevant pharmacokinetic parameters. Results. In vitro, over 80% of sCT was released from the TFCs within 240 min. Super Case-II transport was indicated as the primary release mechanism. Rabbits injected intravenously had C _max, Cls, Vss, and AUC_0-inf values of 75.1 ± 6.5 ng/mL, 20.7 ± 3.3 mL/min, 637 ± 141 mL, and 1925 ± 237 ng*min/mL, respectively. Rabbits dosed via the buccal route had C _max, Cls, and AUC_{0-400 min} values of 4.6 ± 1.6 ng/mL, 22.0 ± 5.9 mL/min, and 842.9 ± 209.7 ng*min/mL, respectively. The relative bioavailability for rabbits treated with the TFCs was 43.8 ± 10.9% with a CV of 24.9%. The reductions in plasma calcium levels after administration of sCT by both the intravenous and buccal route were comparable. Conclusions. The TFCs effectively delivered therapeutically efficacious amounts of sCT across the buccal mucosa in rabbits.     

Intestinal Patches for Oral Drug Delivery

Purpose. Oral route offers an attractive mode of drug administration, although its applications are limited by poor stability of peptides and proteins in the gastrointestinal tract. In this article, we report a novel method based on intestinal patches for oral drug delivery. This method involves the use of millimeter size mucoadhesive patches that adhere to the intestinal wall and direct solute diffusion towards the wall similar to that observed in the case of a transdermal patch. Methods. Intestinal patches were prepared by sandwiching a film of cross-linked bovine serum albumin microspheres between a film of ethyl cellulose and Carbopol/pectin. Delivery of three model drugs, sulforhodamine B, phenol red, and dextran was assessed in vitro using rat intestine. Results. In vitro tests confirmed substantial unidirectional diffusion of model drugs from the patch across the intestinal wall. The presence of ethyl cellulose layer minimized release from the edges as well as from the back side of the patch into the intestinal lumen. In vitro experiments with rat intestine showed that patches were effective in delivering model drugs across the intestine. Trans-lumenal flux of model drugs from intestinal patches was about 100-fold higher compared to that from a solution due to localization of the solute near the intestinal wall and due to minimization of drug loss into the intestinal lumen. Conclusions. Intestinal patches offer a novel approach for oral drug delivery.     

Chitosan Nanoparticles as New Ocular Drug Delivery Systems: in Vitro Stability,in Vivo Fate,and Cellular Toxicity

PURPOSE: To assess the potential of chitosan (CS) nanoparticles for ocular drug delivery by investigating their interaction with the ocular mucosa in vivo and also their toxicity in conjunctival cell cultures. METHODS: Fluorescent (CS-fl) nanoparticles were prepared by ionotropic gelation. The stability of the particles in the presence of lysozyme was investigated by determining the size and their interaction with mucin, by measuring the viscosity of the mucin dispersion. The in vivo interaction of CS-fl nanoparticles with the rabbit cornea and conjunctiva was analyzed by spectrofluorimetry and confocal microscopy. Their potential toxicity was assessed in a human conjunctival cell line by determining cell survival and viability. RESULTS: CS-fl nanoparticles were stable upon incubation with lysozyme and did not affect the viscosity of a mucin dispersion. In vivo studies showed that the amounts of CS-fl in cornea and conjunctiva were significantly higher for CS-fl nanoparticles than for a control CS-fl solution, these amounts being fairly constant for up to 24 h. Confocal studies suggest that nanoparticles penetrate into the corneal and conjunctival epithelia. Cell survival at 24 h after incubation with CS nanoparticles was high and the viability of the recovered cells was near 100%. CONCLUSIONS: CS nanoparticles are promising vehicles for ocular drug delivery.     

壳聚糖包覆的硝酸毛果芸香碱眼用亚微乳的研究

本文设计了一种壳聚糖包覆的硝酸毛果芸香碱眼用亚微乳(chitosan-coated pilocarpine nitrate submicroemulsion,CS-PN/SE),旨在开发一种新型的具有黏膜黏附性的亚微乳眼部给药系统,以延长药物在眼表滞留时间,促进药物的眼部吸收。以中长链甘油三酯(medium chain triglycerides,MCT)为油相,Tween 80为主乳化剂,采用高速剪切工艺制备硝酸毛果芸香碱亚微乳(pilocarpine nitrate submicro emulsion,PN/SE),进一步采用孵育法制备CS-PN/SE,并利用星点设计-效应面优化法进行处方优化。对其粒径、zeta电位、包封率和微观形态进行表征,以新西兰白兔为动物模型,评价了CS-PN/SE在兔眼表滞留特性以及缩瞳作用。眼表滞留特性评价结果显示,与硝酸毛果芸香碱溶液剂组(pilocarpine nitrate solution,PNs)和PN/SE组相比,CS-PN/SE组在眼表的清除率下降,KCS-PN/SE为(0.006 4±0.000 3)min-1,平均驻留时间(mean residence tim...     

Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability

Abstract

Lafutidine a newly developed histamine H2-receptor antagonist having biological half-life of 1.92?±?0.94?h due to its selective absorption from upper part of gastrointestinal tract the development of mucoadhesive sustained release drug delivery system is recommended in order to enhance the bioavailability. A mucoadhesive tablets was developed using the natural polymer, sodium alginate, xanthan gum and karaya gum. Mucoadhesion is a complex phenomenon which involves wetting, adsorption and interpenetration of polymer chains. The prepared tablets of various formulations were evaluated for a total mucoadhesion time, buoyancy lag time and percentage drug released. The formulation with xanthan gum showed better results. Thus, it may be useful for prolonged drug release in stomach to improve the bioavailability and reduced dosing frequency. Non-fickians release transport was confirmed as the drug release mechanism from the optimized formulation by Korsmeyer–Peppas. The optimized formulation (B3) showed a mucoadhesive strength >35?g. In vivo study was performed using rabbits by X-ray imaging technique. Radiological evidences suggest that, a formulated tablet was well adhered for >10?h in rabbit’s stomach. Optimized lafutidine mucoadhesive tablets showed no significant change in physical appearance, drug content, mucoadhesive properties and in vitro dissolution pattern after storage at 40?°C temperature 75?±?5% relative humidity for 3 months.     

复方中药口腔粘膜粘附缓释片的研制与临床观察

目的：为了增加口腔用片对口腔粘膜的粘附力，延长药物对口腔粘膜溃疡的作用时间及提高疗效。方法：将其制成生物粘附片，进行有关质量的检测及临床观察，并与普通片剂进行对照。结果：该制剂粘附力强，吸水膨胀后可粘附于口腔溃疡的创面上，不易移动，既可起到治疗作用，又可保护创面，维持较长的药效。结论：该片剂疗效显示，使用方便。     

Design and formulation of mucoadhesive microspheres of sitagliptin

Mucoadhesive microspheres of sitagliptin (SITCM), a new anti-diabetic drug was prepared with carbopol 934?P using Buchi B-90 nano spray drier and optimized to analyse the key effects and relations of three factors on formulation of SITCM were studied. The appearance of the microspheres was found to be shriveled to nearly spherical, with a narrow size of 2–8?µm. The drug loading and percentage yield was found to be 73?±?0.2% and 92?±?0.3%, respectively. In vitro release indicated Korsmeyer–Peppas pattern mucoadhesion of SITCM-8 was found to be 7.8?±?0.3?h. In vivo studies in rats suggest that the sitagliptin was retained in the gastrointestinal tract for an extended period of time (～12?h) and control group was reduced significantly (～4?h). This study concludes that the mucoadhesive microsphere could be one of the most appropriate drug delivery approaches for the successful delivery of sitagliptin.